12:00 AM
 | 
Feb 25, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Anti-influenza A plasma: Phase II started

NIH began the open-label, U.S. Phase II IRC002 trial to compare 2 units of anti-influenza A plasma plus standard care treatment vs. standard care alone in about 100 patients. NIH's National Institute of Allergy and Infectious...

Read the full 156 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >